Shares of Novavax, Inc. (NASDAQ:NVAX) ended Tuesday session in green amid volatile trading. The shares closed up +0.48 points or 7.09% at $7.25 with 271.91 million shares getting traded. Post opening the session at $6.87, the shares hit an intraday low of $6.79 and an intraday high of $7.25 and the price vacillated in this range throughout the day. The company has a market cap of $1.95 Billion and the numbers of outstanding shares have been calculated to be 271.19 million shares.
Novavax, Inc. (NVAX) on Aug. 09, 2016 announced its financial results for the second quarter and six months ended June 30, 2016.
Novavax Second Quarter Achievements:
- Announced a new seasonal combination respiratory vaccine program. Novavax demonstrated the ability to combine the RSV F and influenza nanoparticle vaccines, bringing together a vaccine approach that induces broadly neutralizing antibodies against both influenza and RSV. Novavax` program was unveiled at the New Approaches to Vaccines for Human and Veterinary Tropical Diseases Keystone Symposia in Cape Town, South Africa in June 2016.
- Continued execution of Resolve(TM), a pivotal Phase 3 trial of our RSV F Vaccine in older adults (60 years of age and older). The Resolve trial is a randomized, observer-blinded, placebo-controlled trial in 11,850 older adults at 60 sites in the United States. The primary efficacy objective is the prevention of moderate-severe RSV-associated lower respiratory tract disease, as defined by the presence of multiple lower respiratory tract symptoms. Enrollment was completed in the fourth quarter of 2015.
- Ongoing execution of a Phase 2 rollover clinical trial of our RSV F Vaccine in 1,330 older adults. The trial is a randomized, observer-blinded, placebo-controlled rollover trial designed to enroll from the population of older adults who participated in the prior Phase 2 trial. The primary endpoints of the trial will evaluate safety and serum anti-F IgG antibody concentrations in response to immunization with our RSV F Vaccine. Enrollment was completed in the fourth quarter of 2015.
- Expanded enrollment of Prepare(TM), a pivotal Phase 3 trial of our RSV F Vaccine in healthy pregnant women, to multiple international sites to take advantage of the RSV season in the southern hemisphere. The Prepare trial is a randomized, observer-blinded, placebo-controlled trial. The primary objective is to determine the efficacy of maternal immunization with our RSV F Vaccine against symptomatic RSV lower respiratory tract infection with hypoxemia in infants through the first 90 days of life. The Prepare trial is supported by a grant of up to $89 million from the Bill & Melinda Gates Foundation (BMGF).
Shares of Bristol-Myers Squibb Co (NYSE:BMY) ended Tuesday session in green amid volatile trading. The shares closed up +0.61 points or 1.08% at $56.96 with 1.66 Billion shares getting traded. Post opening the session at $56.69, the shares hit an intraday low of $56.12 and an intraday high of $57.13 and the price vacillated in this range throughout the day. The company has a market cap of $94.48 Billion and the numbers of outstanding shares have been calculated to be 1.66 Billion shares.
Bristol-Myers Squibb Co (BMY) announced that it will take part in the Morgan Stanley 2016 Global Health Care Conference on Tuesday, September 13, 2016, in New York. Giovanni Caforio, M.D., chief executive officer will make formal remarks about the company and answer questions at 11:10 a.m. EDT.
Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the session will be available later that day.